Simple Summary A novel biomarker panel (Appl1, Sortilin and Syndecan-1) was
demonstrated as a strong independent predictor for both clinical and biochemical …

Simple Summary In prostate cancer (PCa), an accurate patient risk stratification, as well as
the awareness of a possible biochemical recurrence (BCR) event, are crucial to …

The diverse clinical outcomes of prostate cancer have led to the development of gene
signature assays predicting disease progression. Improved prostate cancer progression …

In 2005, the International Society of Urological Pathology (ISUP) introduced several
modifications to the original Gleason system that were intended to enhance the prognostic …

BACKGROUND A new prostate cancer (PCa) grading system (namely, Gleason score‐GS‐
≤ 6 vs. 3+ 4 vs. 4+ 3 vs. 8 vs.≥ 9) was recently proposed and assessed on biochemical …

A plethora of individual candidate biomarkers for predicting biochemical relapse in localized
prostate cancer (PCa) have been proposed. Combined biomarkers may improve …

The objective was to determine the prognostic utility of a new biomarker combination in
prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and …

Background Distinguishing indolent from aggressive prostate cancer remains a key
challenge for decision making regarding prostate cancer management. A growing number of …

Background: Early prediction of disease progression in men with very low-risk (VLR)
prostate cancer who selected active surveillance (AS) rather than immediate treatment could …

Context Prostate cancer stratification is based on tumour size, pretreatment PSA level, and
Gleason score, but it remains imperfect. Current research focuses on the discovery and …